Algorithm for early detection of increased risk of colon cancer in non-adherent patients
CompanyMedial EarlySign, Hod Hasharon, Israel(1)
Roche Deutschland Holding GmbH, Mannheim, Germany(2)
Roche Deutschland Holding GmbH, Mannheim, Germany(2)
Roche distributes ColonFlag, an algorithm developed by Medial Early Sign (MES), to aid in early detection of individuals with a higher probability of harboring colorectal cancer (CRC) than the general population. Colon Flag uses demographics data (birth year and gender) and lab results (current and past CBC results) of eligible patients. The data is sent anonymously to the navify® Algorithm Suite, where the algorithm computes a score which is then converted to a flag if it is above the cutoff value, indicating an increased likelihood of colorectal cancer compared to the general population. The physician should review the score in conjunction with his/her clinical judgment. The algorithm can be automatically integrated into existing IT systems, enabling simple and user-friendly access from the laboratory. In summary, the model enables an early risk assessment of the patient, thereby supporting doctors in clinical decision-making for further assessment. ColonFlag is not a diagnostic or screening device, but rather an indication of relative risk for colorectal cancer, thus a high score does not indicate malignancy or pathology. In addition, a low score for any given person does not indicate low risk or ruling out screening or further testing.
ColonFlag™
www.earlysign.com(1), www.roche.de(2)
Added on: 02-08-2024
[1] https://diagnostics.roche.com/global/en/news-listing/2023/roche-introduces-navify--algorithm-suite--a-digital-library-of-m.html[2] https://navify.roche.com/marketplace/products/algorithms/navify-algorithms-colonflag-by-medial-earlysign
